Company profile for Jiangsu Recbio Technology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Recbio has a high-value vaccine portfolio consisting of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates, etc. The core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines. Recbio is one of the few companies with commercial production capability for novel adjuvants that ha...
Recbio has a high-value vaccine portfolio consisting of HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates, etc. The core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines. Recbio is one of the few companies with commercial production capability for novel adjuvants that have been approved by FDA for human use.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Taizhou, Jiangsu
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.business-standard.com/companies/news/biological-e-recbio-partner-to-manufacture-hpv9-vaccine-125063001107_1.html

BUSINESS STD
30 Jun 2025

https://www.prnewswire.com/news-releases/positive-results-in-the-interim-analysis-of-the-clinical-trial-of-recbios-novel-adjuvanted-recombinant-shingles-vaccine-rec610-in-the-philippines-302023639.html

PR NEWSWIRE
28 Dec 2023

https://www.prnewswire.com/news-releases/jiangsu-recbio-technology-co-ltd-announced-2023-interim-results-report-and-latest-progress-301910777.html

PR NEWSWIRE
27 Aug 2023

https://www.prnewswire.com/news-releases/acceptance-of-clinical-trial-application-for-the-recbios-novel-adjuvanted-recombinant-shingles-vaccine-rec610-in-china-and-overseas-clinical-trial-progress-301886939.html

PR NEWSWIRE
26 Jul 2023

https://www.prnewswire.com/news-releases/two-component-recombinant-covid-19-vaccine-recov-granted-with-emergency-use-authorization-in-mongolia-301776938.html

PR NEWSWIRE
21 Mar 2023

https://www.prnewswire.com/news-releases/clinical-trial-approval-for-the-companys-novel-adjuvanted-recombinant-shingles-vaccine-rec610-in-the-philippines-301705875.html

PRNEWSWIRE
19 Dec 2022

ABOUT THIS PAGE

Contact Jiangsu Recbio Technology and get a quotation

Jiangsu Recbio Technology is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Sulfasalazine bulk offered by Jiangsu Recbio Technology

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty